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Hodgkin lymphoma (HL) is characterized by long survival and
risk of relapse and second neoplasm. The aim of this study is to
evaluate the possibility of improving the accuracy of ﬁne-needle
cytology (FNC) in HL follow-up using Power Doppler ultrasound
(US) assistance and immediate microscopic evaluation (ICE).
The study was performed in two consecutive groups of 200
FNC in HL patients. In the ﬁrst group FNC of palpable lymph-
nodes or extra lymph-nodal masses were performed without US
assistance except for impalpable and/or deep located masses
(nonassisted group); In the second group, all the FNC were per-
formed under Power Doppler US assistance with ICE and imme-
diately repeated in inadequate cases (assisted group). Cytologi-
cal diagnoses were controlled by histology (61) or clinical
follow-up (69); sensitivity and speciﬁcity were calculated in the
two groups and to evaluate the effect of Power Doppler alone,
adequate cases were compared with the total number of FNC in
each of the two groups.
FNC identiﬁed 90 negative cases, 3 false negatives, 70 HL
relapse, 16 inadequate and 14 suspicious; second neoplasia
were diagnosed in 12 cases and all histologically conﬁrmed.
Sensitivity and speciﬁcity were 64 and 84% in the nonassisted
group and 86 and 94% in the assisted group and there were sig-
niﬁcant differences between the number of adequate cases v.s.
the total number of FNC in each of the two groups.
Sensitivity and speciﬁcity in assisted FNC are higher than in
nonassisted ones. The main advantage of assisted FNC in the
follow-up of HL is to produce accurate diagnoses avoiding inva-
sive biopsies. Diagn. Cytopathol. 2008;36:467–472.
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Hodgkin lymphoma (HL), in its initial and limited stages,
is nowadays a curable disease.1–3 In fact, because of
timely diagnoses, accurate staging, and high quality treat-
ments, more than 80% of HD patients may recover from
the disease.1–3 Nonetheless, HD patients, because of their
frequent young age and the received treatments, require a
special form of extended follow-up.1,4 This follow-up is
aimed at the prevention and detection of HL recurrences
and the treatment-related late effects including second ne-
oplasia.4 Fine-needle cytology (FNC) combined with phe-
notypic and molecular techniques have progressively
gained an important role as ﬁrst step and follow-up proce-
dure in the diagnosis of lymphadenopathies. In many
Institutions, a percentage of non-Hodgkin lymphomas
(NHL) are diagnosed and classiﬁed by FNC5–10; neverthe-
less this technique has a less relevant and more controver-
sial role in the diagnosis of HL.3,11,12 In fact, the sensitiv-
ity of the method is extremely variable, ranging between
30 and 90% in the series available in literature11–21 and,
from a practical point of view, HL is responsible for at
least 30% of the false negatives in FNC diagnoses of lym-
phoprolipherative processes.11 Nonetheless, FNC remains
a widely used instrument in the diagnosis of lymphoproli-
ferative processes and continues to deal with HL and its
diagnostic problems. Moreover HL, in cases of complete
remission or in relapsed cases, requires a careful follow-
up in which lymphadenopathies, or nonlymphnodal swel-
lings, may arise from different pathologies such as
reactive processes, relapses of HL, and even second neo-
plasms. Other noninvasive instruments are widely used in
the diagnosis and staging and follow-up of HL, such as
ultrasound (US), computed tomography (CT), and posi-
tron emission tomography scan (PET); these tools are
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generally highly sensitive but they are not speciﬁc, there-
fore treatment decisions are not based solely on imaging
techniques.22–24 In this perspective, FNC, because of its
reliability, handiness and bearably, may contribute to the
prebiopsy or presurgical diagnosis of these processes.
The aim of this study, therefore, has been to assess the
role of FNC in the diagnosis of lymphadenopathies and
extra lymph-nodal masses in the follow-up of HL and to
evaluate the possibility of improving the accuracy of the
method through a comprehensive clinical, instrumental,
and cytological approach.
Materials and Methods
From the ﬁles of the Dipartimento di Anatomia ed Istologia
Patologica e Citopatologia of the University of Naples
‘‘Federico II,’’ 200 cytological samples from 130 patients
with a previous diagnosis of HL in the ten year period from
1997 to 2006 were retrieved. In all patients, the primary di-
agnosis of HL had been histologically proven and HLs
were classiﬁed according to the Revised European-Ameri-
can classiﬁcation of lymphoid neoplasm.25 The series
included for 69 (57%) males and 61 (43%) females, with a
median age of 45 years (ranging from 16–74); clinical data
are summarized in Table I. After diagnosis and staging, all
the patients had received HL therapy in the Haematology
Department of the same Medical School according to the
standard treatments (early stages: ABVD 3 4 cycles fol-
lowed by radiotherapy, advanced stages ABVD 3 6 cycles
followed by radiotherapy on bulky sites). The new masses
appeared after a median time of 36 months (range 9–108)
from the initial histological diagnosis of HL. The targeted
anatomical sites were:154 lymph-nodes and 46 extra
lymph-nodal sites FNC (Table II). Extra lymph-nodal tar-
gets concerned thyroid,11 breast,9 soft-tissues,10 liver,3
lung,2 salivary gland,2 abdominal deep located masses,3
testis2 spleen,2 kidney,1 and ovary1 (Table II). The study
was retrospectively performed comparing two consecutive
groups of FNC in HL patients. In the ﬁrst group FNC of
palpable lymph-nodes or extra lymph-nodal masses were
performed without US assistance whereas FNC of impalpa-
ble and/or deep located masses were performed under US
guide in the Radiology Department; in these cases the US
procedures were performed using a portable Spazio-Hitachi
equipment and a 3.5 HMz curvilinear probe. In the second
group all the US procedures were performed with an US
Hitachi instrument equipped with harmonic computed tech-
nology Power Doppler (EUB 6500; Hitachi, Tokyo, Japan)
and a 13–6 MHz broad and linear probe (EUB 54M probe;
Hitachi) for superﬁcial targets or a 5–2 MHz broad-band
curvilinear probe (EUB 514C probe; Hitachi) for deep-
seated targets. All the FNC of the second group were per-
formed under US control using this high resolution Power
Doppler equipment by a team made of a hematologist and a
cytopathologist. This high resolution US equipment, com-
bining tissue harmonic compound and Power Doppler so-
nography allows an accurate evaluation of morphology
(including size, shape and hilar or cortical deformation) and
vascular characteristics of the lymph nodes and hence it is
possible to select the areas most suspected of malignancy
(Fig. C-1).26 Because one of the goals of the study was to
evaluate the possible beneﬁt of US high resolution and
Power Doppler US-assistance, cases in which FNC had
been performed under CT control were not considered in
the present study. In all the cases of the second group, the
ﬁrst smear was immediately Diff-Quik stained and eval-
uated (ICE) while the patient was still in the outpatient
ofﬁce; ICE identiﬁed four inadequate cases (scantily or non
cellular and/or, blood contaminated) which were repeated
and classiﬁed accordingly. ICE also oriented the applica-
tion of ancillary techniques; in fact, when possible, another
two or more extra slides were prepared, alcohol 958 ﬁxed
and used for immunocytochemistry (ICC). In 20 cases in
which a NHL was considered in the differential diagnosis, a
further pass was ﬂushed in buffer solution and used for
ﬂow cytometry (FC). ICC was performed in 28 cases using
CD30 and CD15 (LEU-M1) (1:100) (Dakopatts, Glostrup,
Denmark). FC was performed using the following com-
bined ﬂuoresceinated antibodies CD3, CD4, CD5, CD8,
CD10, CD19, CD23, FMC7, bcl-2, kappa and lambda light
chains (Becton Dickinson, San Jose´, California). Cytologi-
cal diagnostic categories were as follows: positive for ma-
lignant cells consistent with HL, positive for malignant
cells consistent with another (non-HL) neoplasm, suspi-
cious for HL recurrence, negative for malignant cells and/
or reactive hyperplasia in lymph-nodal FNC, negative with
or without further speciﬁcation in other non lymph-nodal
Table I. Baseline Patient Characteristics in the Two Study Groups
FNC characteristic Total no. Nonassisted group Assisted group
No. of cases 200 104 96
No. of patients 130 69 61
Gender (M:F) 69:71 37:32 33:28
Age range (year) 16–74 19–74 16–72
Lymph-nodal 154 78 76
Extra lymph-nodal 46 24 22
Table II. Lymph-Nodal and Non Lymph-Nodal FNC Sites
Lymph-nodal No. Non lymph-nodal No.
Cervical 54 Thyroid 11
Axillary 42 Soft-tissue 10
Supra-clavear 17 Breast 9
Sub-mandibular 4 Liver 3
Parotideal 4 Lung 2
Retronucal 1 Salivary gland 2
Intramammarian 2 Testis 2
Inguinal 27 Abdominal masses 3
Spleen 2
Ovary 1
Kidney 1
Total 154 46
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FNC and inadequate. All the cytological diagnoses were
conﬁrmed by clinical follow-up and by histology in 61
cases. FNC were generally well tolerated by the patients
without complications even in splenic FNC, which were
performed as previously described.27 Sensitivity and speci-
ﬁcity in the two groups were calculated and a statistical
analysis was performed to evaluate the different diagnostic
efﬁciency in the two groups. Moreover, to evaluate the
effect of Power Doppler alone without the contribute of
ICE, we compared the number of adequate cases versus the
total number of FNC in each of the two groups using the
Chi-square test.
Results
Diagnostic distribution of the two consecutive series (200
samples) was as follows: 90 negative, HL relapse in 68
cases; 14 HL suspects, 16 inadequate and 12 s neoplasm
(Table III). The 68 HL relapse cases included 56 lymph-
nodal FNC and 12 extra lymph-nodal FNC which
included soft tissues,8 breast,2 liver,1 and spleen1; in all
these cases the diagnosis was based on the identiﬁcation
of Reed-Sternberg (RS) cells in a speciﬁc background
(Figs. C-2 and C-3), further conﬁrmed by CD15 and
CD30 positivity (Fig. C-4) when possible. The cytological
diagnoses were conﬁrmed by histological examination in
30 cases and by clinical follow-up in the remaining 38
cases. In these latter negative cases, clinical and US
examinations assessed the regression of clinical and
instrumental signs mainly represented by lymph-nodal
swellings. In 14 cases, diagnosed as suspicious, no classi-
cal RS cells were observed in the smears but only scanty
or even single atypical mononucleated cells in an inﬂam-
matory background. These cases concerned lymph-nodes11
and soft tissue swellings.3 In these suspect cases, subse-
quent histological examination conﬁrmed the cytological
suspect of HD in 9 cases (64%), whereas the remaining 5
cases (34%) were reactive processes. Twelve inadequate
cases were collected in the nonassisted group; conversely,
four inadequate cases of the second group were immedi-
ately repeated, evaluated and distributed in the corre-
sponding diagnostic categories (Table IV). Second neo-
plasm were diagnosed in 12 cases; this was an heteroge-
neous category which included breast carcinoma,2 kidney
carcinoma,1 lymph-nodal metastases from carcinoma of
the tongue1 and head, and neck squamous-cell carci-
noma,2 hepatic metastasis from lung adenocarcinoma,
NHL,2 thyroid papillary carcinoma2 thyroidal Hurthle cell
adenoma,1 and ovarian cystic serous tumor.1 The remain-
ing 90 cases, diagnosed negative, included 78 lymph-
nodal FNC diagnosed as reactive hyperplasia and 12
extra-nodal FNC samples diagnosed negative for HD.
These latter included other benign processes such as
breast steatonecrosis,2 gynecomastia,2 spermatocele1 and
thyroidal nodular goiter.4 Among these cytological nega-
tive cases there were three false negatives: two in deep
located abdominal lymph-nodes and one case of hydrocele
caused by testicular neoplasm. Diagnostic distribution of
FNC in the two study groups is summarized in Table IV.
As for the temporal and clinical distribution of cytological
diagnosis, in most of the cases just one FNC was per-
formed. In 19 patients, two or more FNC were performed
during the 10-year period; seven of these cases developed
two relapses of HL. Three patients underwent to three
FNC with two diagnosed relapses, another three patients
underwent three FNC with three relapses in two cases. In
six patients, two FNC in two distinct sites were performed
at the same time: in four cases both the FNC concerned
palpable lymph-nodes whereas the other two cases con-
cerned lymph-nodes and soft tissues (buttock and scapular
soft tissue swellings, respectively). Sensitivity and speci-
ﬁcity were then calculated in the two different groups
with the following results: 64 and 84% in the nonassisted
group and 86 and 94% in the assisted group, respectively
(P < 0.05). As far as the effect of Power Doppler con-
cerns, there were signiﬁcant differences in the frequencies
between the number of adequate cases versus the total
number of FNC in each of the two groups (P < 0.05).
Discussion
Although cytological features of HL are well known and
extensively described,11–20 the role of cytology in the di-
agnosis of HL is still controversial. Low diagnostic sensi-
tivity and difﬁcult or impossible identiﬁcation of speciﬁc
sub-types represent the main limitations of the tech-
nique.11–13 Nonetheless, FNC is extensively used in the
diagnosis of lymphadenopathies and lymphoproliferative
processes, and as HL is part of these processes, inevitably
Table III. Cytological Diagnosis of the Whole Series
Hodgkin lymphoma relapse 68
Hodgkin lymphoma suspect 14
Second neoplasm 12
Inadequate 16
Negative 90
Total 200
Table IV. Diagnostic Distribution in the Two Study Groups
Cytological diagnoses No.
Non assisted
group
Assisted
group P
Reactive hyperplasia 75 35 40 N.S.
False negative 3 3 0 N.S.
Negative, other benign
pathologies
12 7 5 N.S.
Hodgkin lymphoma relapse 68 32 36 N.S
Second neoplasm 12 4 8 <0.05
Hodgkin lymphoma
suspected
14 9 5 <0.05
Inadequate 16 12 4 <0.05
Total 200 102 98
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cytologists face HL with its diagnostic problems. Apart
from the role in the primary diagnosis, FNB has another
role in the follow-up of HL which may be of great clini-
cal relevance. In fact, combination chemotherapy (CT)
and extensive radiotherapy (RT) have greatly improved
the survival rate and increased complete remissions of
HL.1–3 Nonetheless, these patients require a careful fol-
low-up in which any lymph-nodal enlargement or other
clinical process are approached with a greater attention
compared with that reserved to non-HL patients and, in
general, to nononcological patients even when they arise
in an evident and/or reassuring clinical context. On the
other hand, advanced stage HL has a high risk of new
lymph-nodal or extra-lymph-nodal localizations.28–30
Finally, HL patients, as late effects of treatment, have an
increased risk of hematological and nonhematological sec-
ond malignancies, which increases through time and
requires prolonged clinical-pathological survival.31–33 In
hematological dedicated Institutions, FNC is generally
considered insufﬁcient for the primary diagnosis of HL
and histology is always required3 but there are divergent
opinions regarding the diagnostic strategies in HL patients
who develop lymphadenopathies or swellings whether
they are or are not suspected of HL relapse. In fact, in
these cases, surgical biopsies may be either ‘‘too much’’
or ‘‘too little’’ especially when the targets are deeply
located or not easily reachable; conversely FNC may pro-
duce a deﬁnite diagnosis avoiding useless and more inva-
sive diagnostic procedures. Therefore reactive processes,
HL relapses and second malignancies represent the main
targets of FNC when dealing with HL patients. As
reported in the literature,11–20 the cytological diagnosis of
HL may be hampered by different factors such as speciﬁc
histological sub-type, shortage of diagnostic cells, hidden
or masked diagnostic cells, and possible unspeciﬁc ICC.
In fact in nodular sclerosis, which represents the most
common histological subtype of HL, ﬁbrosis and random
distribution of diagnostic RS cells may hamper the cyto-
Figs. C-1–C-4. Fig. C-1. Localized neoangiogenesis in a lymph-node partially involved by Hodgkin’s lymphoma as revealed by Power Doppler US.
Fig. C-2. HL cytological features: atypical mononucleated and multinucleated nucleolated cells in a proper background (Diff-Quik stain 3106). Fig.
C-3. Classical RS cell in lymphocytic background (Diff-Quik stain 3430). Fig. C-4. Immunocytochemical stain of HL: C-CD30 positive RS cells con-
ﬁrming the cytological diagnosis of HL (APAP 3430).
ZEPPA ET AL.
470 Diagnostic Cytopathology, Vol 36, No 7
Diagnostic Cytopathology DOI 10.1002/dc
logical integrity, the harvest and examination of diagnos-
tic cells. RS cells may also be scanty and the presence in
a cytological sample of variants such as ‘‘atypical mono-
nuclear nucleolated’’ or ‘‘hyperlobated’’ may suggest HL
but might not be sufﬁcient for a deﬁnitive diagnosis of
HL. These difﬁculties are enhanced in the ‘‘lymphocytic
predominance’’ variant in which there is a prevalence of
lymphocytes and absence of classic RS cells.34 In ordi-
nary cases, RS cells and their variants are generally inter-
spersed in a reactive back-ground made-up by lympho-
cytes, plasma cells, eosinophils, neutrophils, histiocytes,
and epithelioid cells; their amounts varying from case to
case.16,17,35–40 This complex background may hide the RS
cells giving rise to false-negative.17,35,36,38 Conversely
atypical cells, mimicking RS cells may be observed in re-
active lymph-nodes or NHL such as anaplastic ‘‘K1’’ lym-
phoma, melanoma and some undifferentiated carcino-
mas.39 All these difﬁculties may probably cause the
extreme variability of sensitivity in the different experien-
ces reported in the cytological diagnosis of HL.11–20 In
this study, sensitivity and speciﬁcity obtained in the
assisted group are higher than those obtained in the non-
assisted group as well as those reported in literature,11–20
and different factors may have determined this improve-
ment. First of all, clinical history has probably inﬂuenced
the whole procedure determining a higher and probably
‘‘dedicated’’ attention; moreover, in cases of HL relapse,
diagnostic criteria may be less strict compared with those
ones requested for primary diagnosis of HL34 resulting in
an general diagnostic advantage. Moreover modern high
resolution US instruments equipped with harmonic com-
puted technology and Power Doppler, other than to guide
the needle in the impalpable masses, enables to select the
most signiﬁcant areas to biopsy. Abnormalities of mor-
phologic structures (abnormal shapes, hypoechogenicity,
hilar asymmetry, irregular margins) and vascular struc-
tures (chaotic vascular pattern) are US ﬁndings suspected
for malignancy in lymphadenopathies and become
selected targets for US-guided FNC. In fact, as reported
above, in this study the use of US Power Doppler has
determined a signiﬁcant improvement of efﬁciency (P <
0.05). As far as the second malignancies, because of their
clinical and histological heterogeneity, they may cause
diagnostic difﬁculties in Institutions mainly or totally
dedicated to hematological pathologies. These difﬁculties
are enhanced in case of ‘‘unusual’’ second malignancies
or nonlymphomatous processes. In fact ‘‘typical’’ second
malignancies closely related to the iatrogenic effects such
as leukemia, head and neck tumors or breast carcinomas
are well known and in some way ‘‘expected.’’ Conversely
‘‘atypical’’ second neoplasm such as in this series, renal
carcinoma and other nonmalignant processes such as
inﬂammatory psedotumour or gynecomastia were unex-
pected and correct FNC diagnoses changed the clinical
planning and increased the sensitivity. As far as the ancil-
lary techniques are concerned, according to other experi-
ences,11,12 ICC may be helpful in the cytological diagnosis
of HL with some limitations. In fact in nodular sclerosis,
mixed cellularity and lymphocyte depletion variants, diag-
nostic cells are generally CD30 and CD15 positive but in
the lymphocytic predominance sub-type they are CD30
negative but CD45 and B-markers (CD20, CD19) positive.
These cells, apart from their phenotype, may mimic follic-
ular-centre cells on cytological samples and therefore may
be missed causing a percentage of false-negative in our as
well as in other series.11–14,18 As far as the other sub-types
are concerned, others ICC studies have demonstrated the
reliability of CD30 and CD 15 on cytological samples to
detect RS cells11,12 whereas bad preservation and short-
age of diagnostic cells may hamper ICC even in these
subtypes. In our study ICC has been utilized in a limited
number of cases28 which represents just 14% of the
whole series mainly because of the above reported limita-
tions. Nonetheless, when utilized, ICC has been highly
effective either in the identiﬁcation of diagnostic cells or
in conﬁrming negativity. FC has dramatically changed
the cytological diagnosis of NHL, but as foreseeable,
does not contribute in the same manner to the diagnosis
of HL.11 In fact diagnostic cells are too scanty to form an
identiﬁable gate of cells; moreover they are too large and
probably get broken or stick to the tubes along the proce-
dure. As for the reactive lymphoid cells in HL, some FC
studies have observed a prevalence of CD4+ T-lympho-
cytes and a small amount of polyclonal B-cell.41,42 In our
four cases, we obtained similar same results with CD4
prevalence in three out of four of the tested cases, but we
think this phenotypic pattern may contribute to the exclu-
sion of a NHL but does not help the HL diagnosis. As
reported above, we did not perform cytological classiﬁca-
tions of speciﬁc subtypes; some studies have tried to with
variable results.21,40 Nonetheless, LH sub-classiﬁcation
has a limited value in post-primary HL in which staging
and clinical data are more relevant therefore, in HL fol-
low-up, the simple diagnoses of positive or negative for
HL may be sufﬁcient for clinical management.1,2 In con-
clusion, FNC is a simple and accurate tool to use in the
follow-up of HL and it is improved by US Power Doppler
guide and ICE. Among the ancillary techniques, ICC is
the most useful provided that a sufﬁcient number of diag-
nostic cells are present. The relevance of FNC in HL
patients is related to the determination of diagnostic-ther-
apeutic decisions, avoiding mainly in cases of relapse or
in reactive processes, more invasive and expensive diag-
nostic procedures.
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